BEKE vs EQIX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BEKE's deterministic health scores signal significant distress: the Piotroski F-Score of 3/9 indicates weak financial health, with deteriorating profitability and negative earnings growth. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given the company's declining earnings and high payout ratio. While the Graham Number ($9.15) suggests undervaluation, the current price of $16.90 trades at a substantial premium, reflecting overoptimistic growth expectations. Analysts recommend 'buy' with a target of $20.68, but this is inconsistent with the company's weak fundamentals and negative earnings trajectory. The stock has underperformed over multiple time horizons, including a 5-year decline of 73.3%.
EQIX shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
BEKE vs EQIX: Head-to-Head Comparison
This page compares KE Holdings Inc. (BEKE) and Equinix, Inc. (EQIX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.